RxDoctor Payments Data

Joseph Phillips

Optometrist · Oklahoma City, OKNPI 1407803703

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (58.7%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Alcon accounts for 87.8% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2019 at $25,576 and has fallen 94.8% since, to $1,339 in 2025. Among optometrist clinicians in OK with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$52,465in general payments, 2019–2025

Across 324 payments — averaging $161.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$46K
  • Johnson & Johnson Vision Care, Inc.$4K
  • Coopervision Inc.$443
  • Bausch & Lomb Americas Inc.$431
  • AbbVie$328
  • ABB Con-cise Optical Group LLC$172
  • plus $703 from 10 others

What the payments were for

  • Consulting fees$30,79859%
  • Speaking & faculty fees$6651%
  • Travel & lodging$8,49716%
  • Food & beverage$12,48924%
  • Entertainment$170%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$52,465 in reported general payments places this provider in the 95th percentile of 714 optometrist providers in Oklahoma.

See all optometrist providers in Oklahoma

Medicare billing

Part B allowed, 2024
$18,107
Medicare patients
127
Services billed
238

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine22$25,899
Brimonidine Tartrate14$1,784
Latanoprost19$151

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis$328$25,89922 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 714 optometrist providers in Oklahoma.

Other optometrist in Oklahoma City

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →